CAR T-Cell Therapy Market Share

On the basis of regional analysis, the CAR T-cell therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

The market for CAR T cell therapy is predicted to hold the leading share in the North America industry is predicted to account for largest revenue share by 2037, attributed to growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA).are estimated to further boost the market growth. For instance, Kymriah is a CAR T cell therapy manufactured by Novartis and approved by the FDA in 2017. The therapy is for the treatment of acute lymphoblastic leukemia. The market in Europe is anticipated to hold the second largest share in the market as a result of growing approvals of CAR T cell therapies such as Kymriah and Yescarta by the European Medicines Agencies (EMA), which is further predicted to increase the CAR T-cell therapy market size over the coming years.